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Abstract
Purpose Tacrolimus and everolimus are widely used to prevent allograft rejection. Both are metabolized by the hepatic cyto-
chrome P450 (CYP) enzyme CYP3A4 and are substrate for P-glycoprotein (P-gp). Drugs influencing the activity or expression
of CYP enzymes and P-gp can cause clinically relevant changes in the metabolism of immunosuppressants. Several case reports
have reported that flucloxacillin appeared to decrease levels of drugs metabolized by CYP3A4 and P-gp. The magnitude of this
decrease has not been reported yet.
Methods In this single-center retrospective cohort study, we compared the tacrolimus and everolimus blood trough levels
(corrected for the dose) before, during, and after flucloxacillin treatment in eleven transplant patients (tacrolimus n = 11 patients,
everolimus n = 1 patient, flucloxacillin n = 11 patients).
Results The median tacrolimus blood trough level decreased by 37.5% (interquartile range, IQR 26.4–49.7%) during
flucloxacillin treatment. After discontinuation of flucloxacillin, the tacrolimus blood trough levels increased by a median of
33.7% (IQR 22.5–51.4%). A Wilcoxon signed-rank test showed statistically significantly lower tacrolimus trough levels during
treatment with flucloxacillin compared with before (p = 0.009) and after flucloxacillin treatment (p = 0.010). In the only available
case with concomitant everolimus and flucloxacillin treatment, the same pattern was observed.
Conclusions Flucloxacillin decreases tacrolimus trough levels, possibly through a CYP3A4 and/or P-gp-inducing effect. It is
strongly recommended to closely monitor tacrolimus and everolimus trough levels during flucloxacillin treatment and up to
2 weeks after discontinuation of flucloxacillin.
Keywords Tacrolimus . Everolimus . Flucloxacillin . CYP3A4 . Drug-drug interaction . Blood trough levels . Therapeutic drug
monitoring
Introduction
The calcineurin inhibitor tacrolimus and the mammalian target of
rapamycin (mTOR) inhibitor everolimus are widely used in organ
transplantation to prevent allograft rejection [1]. Because both im-
munosuppressants have a narrow therapeutic window and show
great inter- and intraindividual variability in pharmacokinetics, fre-
quent monitoring of blood drug levels is required [2]. Tacrolimus
and everolimus are primarily metabolized by hepatic cytochrome
P450 (CYP) enzymes and are substrates for P-glycoprotein (P-gp)
[2–4]. Drugs influencing the activity or expression of CYP en-
zymes or P-gp can cause clinically relevant changes in immuno-
suppressant metabolism resulting in toxic or subtherapeutic tacro-
limus and everolimus blood levels [5].
Due to immunosuppressants, transplant patients are at in-
creased risk for bacterial infections and flucloxacillin is a rela-
tively frequently used antibiotic. This small-spectrum antibiotic
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of the isoxazolyl-penicillin type is used to treat Gram-positive
bacterial infections. Although CYP3A4 is involved in the me-
tabolism of flucloxacillin, the drug itself does not show inhibi-
tion of CYP P450 isoenzymes, as shown by in vitro assays
[6–8]. However, several cases have been reported in which
flucloxacillin appeared to decrease levels of drugs metabolized
by CYP3A4, such as voriconazole, cyclosporin A, and quini-
dine [8–11]. These findings suggest that flucloxacillin might be
a CYP3A4 inducer. In fact, all clinically relevant doses of
flucloxacillin appear to induce CYP3A4 and P-gp through the
activation of nuclear PXR (Pregnane X Receptor) [8].
Recently, we observed subtherapeutic trough levels of both
everolimus and tacrolimus during flucloxacillin treatment in an
11-year-old transplant patient. At the age of 18 months, he had
received a living-related combined kidney and liver transplant be-
cause of primary hyperoxaluria type 1. He was treated with pred-
nisolone, everolimus, and tacrolimus to prevent allograft rejection.
After placement of a nephrostoma at the age of 11, he presented at
the outpatient clinic with recurrent episodes of Staphylococcus
aureus pyelonephritis. Based on antibiogram results, he was treated
with flucloxacillin. After starting flucloxacillin, trough levels of
everolimus and tacrolimus decreased from 5.3 to 1.5μg/L and from
2.9 to 2.3μg/L, respectively, despite a dose increase of 1mg/day for
everolimus and 1 mg/day for tacrolimus. After discontinuation of
flucloxacillin, the trough levels of everolimus and tacrolimus in-
creased spontaneouslywithin 3 days. Seven days later, trough levels
increased even further, reaching values of 8.1 μg/L for everolimus
and 7.1μg/L for tacrolimus (target trough levels for everolimus and
tacrolimus were 4–6 μg/L and 3–5 μg/L, respectively). A compre-
hensive PubMed database search for drug-drug interaction between
flucloxacillin and tacrolimus or everolimus led to no results. Later,
while conducting this study, we found a case series of 4 adult heart
transplant patients reporting a decrease in tacrolimus (n =4) and
everolimus (n =1) blood trough levels during flucloxacillin treat-
ment [12]. In their study, Gellatly et al. hypothesize that this is
caused by the CYP3A4-inducing properties of flucloxacillin [12].
We hypothesized that the changes in tacrolimus and evero-
limus trough concentration in our case were caused by induc-
tion of CYP3A4 by flucloxacillin. In order to support this
hypothesis and to provide additional evidence of this potential
drug-drug interaction, we conducted a single-center retrospec-
tive cohort study in which the effect of flucloxacillin on whole




This single-center retrospective cohort study was performed at
the University Medical Center Groningen (UMCG),
The Netherlands. In this hospital, the following numbers of
transplantations were performed in 2018: kidney n = 166, liver
n = 73, lung n = 35, pancreas n = 9, heart n = 8, small bowel
n = 2, and stem cell transplantations n = 183 [13].
We intended to include all solid organ and allogeneic stem
cell transplantation patients who were treated with
flucloxacillin while receiving immunosuppression with tacro-
limus and/or everolimus in the period of between January and
December 2018. Patients were identified using a query in the
hospital electronic information system. Information on trough
levels of tacrolimus and everolimus were obtained 1 year be-
fore, during, and up until 1 year after treatment with
flucloxacillin. Due to the retrospective and descriptive nature
of this study, the need to provide informed consent was
waived by the UMCG medical ethics committee (METc
2019/199).
The following exclusion criteria were applied:
– Use of the following known CYP inhibitors/inducers as
defined by the Dutch National Pharmacists Database: car-
bamazepine, efavirenz, enzalutamide, phenobarbital, phe-
nytoin, hypericum, mitotane, nevirapine, primidone,
rifabutin, rifampicin, cobicistat, caspofungin, etravirine,
sevelamer, clarithromycin, cobicistat, erythromycin,
itraconazole, ketoconazole, ritonavir, voriconazole,
chloramphenicol, danezole, diltiazem, felodipine, flucon-
azole, nifedipine, posaconazole, imatinib, and grapefruit
juice [14]
– Decreased liver function, increased transaminases
(ALAT > 50 U/L, ASAT > 45 U/L), or enteritis/colitis
during treatment with flucloxacillin, since significant
CYP450 metabolism takes place in liver and intestine
[3, 15]
– Patients younger than 1 year of age, due to immature
CYP450 function in infants [16]
Clinical characteristics
For each patient, data regarding gender, age, transplant type,
transplant date, body mass index (BMI), blood-drug levels,
and corresponding doses of tacrolimus and everolimus were
collected from the electronic health records (EHR). All tacro-
limus and everolimus whole blood trough levels were deter-
mined as part of routine care by validated LC-MS/MS analysis
at the UMCG [17].
Outcomes
Because immunosuppressants show great interindividual var-
iability in blood trough levels, trough levels were normalized
for the dose by dividing the trough level (μg/L) by the dose
(mg), giving the unit trough level/dose (μg/L/mg). This meth-
od allows comparison between patients [18].
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The following indicators were determined to quantify the
effect of flucloxacillin on tacrolimus trough levels [19].
1. The number of patients with a decrease in tacrolimus or
everolimus trough levels during flucloxacillin treatment.
A decrease was defined as a lower mean whole blood
trough level/dose during flucloxacillin treatment com-
pared with a maximum period of 1 year before start of
flucloxacillin treatment.
2. The number of patients with an increase in tacrolimus or
everolimus whole blood trough levels after flucloxacillin
treatment. An increase was defined as a higher mean
whole blood trough level/dose for a period up to 1 year
after flucloxacillin treatment, compared with during
flucloxacillin treatment.
3. The tacrolimus or everolimus mean trough level before,
during and after treatment with flucloxacillin, corrected
for the tacrolimus or everolimus dose. The mean blood
trough levels/dose before flucloxacillin treatment consists
of the mean of the available tacrolimus or everolimus
trough levels up to 1 year before flucloxacillin treatment,
divided by the dose at time of trough concentration sam-
pling. The mean blood trough levels/dose during
flucloxacillin treatment consists of all available tacrolimus
or everolimus trough levels during flucloxacillin treat-
ment starting from the day after start of flucloxacillin
treatment until the last day of flucloxacillin treatment.
The mean tacrolimus or everolimus trough levels/dose
after flucloxacillin treatment consists of all the available
trough levels divided by dose starting from 1 day after
discontinuation of flucloxacillin up to 1 year after discon-
tinuation of flucloxacillin.
4. Median tacrolimus or everolimus blood trough levels,
corrected for the dose, before, during, and after treatment are
calculated in a comparable manner to the description above.
5. The mean and median before/during flucloxacillin ratios,
calculated by dividing the median (or, respectively, the
mean) of tacrolimus and everolimus blood trough level/
dose before flucloxacillin treatment by the median (or,
respectively, the mean) of blood trough level/dose after
flucloxacillin treatment. These values are used to quantify
the change in tacrolimus or everolimus blood trough
levels/dose. The same ratios were calculated during and
after flucloxacillin treatment.
6. The median ratios were converted to a percentage change of
tacrolimus or everolimus whole blood levels. The median
percentages are given with an interquartile range (IQR).
Statistical analysis
Mean andmedian tacrolimus or everolimuswhole blood trough
levels divided by the immunosuppressant dose before, during,
and after flucloxacillin treatment were calculated and com-
pared. The normality of the distribution of the immunosuppres-
sant blood trough levels divided by the dose, per group, was
tested by conducting a Shapiro-Wilk normality test. Statistical
significance was set at p < 0.05. Based on the type of distribu-
tion and the sample size, a non-parametric Wilcoxon signed-
rank test and/or a parametric paired t test were performed to
compare the mean values of the groups (p < 0.05) [19]. The
distribution of each group was plotted in a box plot to allow
visual comparison of median values and the overall values. All
statistical analyses were performed with IBM SPSS statistics
version 23 (Armonk, NY: IBM Corp, USA). All categorical
data were expressed as percentages. Numeric data were
expressed as mean ± standard deviation (SD) or as median with
min-max and IQR, as appropriate.
Results
Eleven patients, including the case described in the
“Introduction” section, were identified by applying the
predefined criteria. All included patients used tacrolimus.
Apart from the index patient, no other patient was treated with
everolimus. The patient characteristics are shown in Table 1.
One subject (patient 6) had no available data on tacrolimus
trough levels before flucloxacillin use. Data were complete for
ten patients. In nine of the eleven patients, there was a de-
crease in tacrolimus trough levels during flucloxacillin treat-
ment. After discontinuing flucloxacillin, ten patients showed
an increase in tacrolimus trough levels. Data on individual
patients are shown in Online Resource 1.
The mean tacrolimus blood trough level corrected for the
dose before flucloxacillin was 2.3 μg/L/mg (± 1.6), during
treatment 1.3 μg/L/mg (± 1.0), and after treatment 1.9 μg/L/
mg (± 1.4). Themedian tacrolimus blood trough level dropped
by 37.5% (IQR 26.4–49.7%) during flucloxacillin treatment.
After discontinuation of flucloxacillin treatment, the median
tacrolimus blood trough level increased by 33.7% (IQR 22.5–
51.4%). Table 2 shows the values of the measured outcomes.
Online Resource 2 shows a box plot of these data. Changes in
tacrolimus blood trough levels/dose are shown in Fig. 1. All
but one patient (patient 8) showed a lower tacrolimus trough
level divided by dose during flucloxacillin treatment.
The Shapiro-Wilk test of normality indicated that all three
groups had a normal distribution (p > 0.05) of mean blood
trough levels (before flucloxacillin p = 0.32, during
flucloxacillin p = 0.39, and after flucloxacillin p = 0.29).
Mean blood trough levels/dose before, during, and after
flucloxacillin use was compared with both a paired t test and
a non-parametric test because of the small sample size.
Both tests showed a significant difference in mean tacroli-
mus blood trough levels corrected for dose before and during
flucloxacillin treatment (paired t test: p = 0.006, Wilcoxon:
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p = 0.009); a significant difference between, during, and after
flucloxacillin treatment (paired t test: p = 0.003, Wilcoxon:
p = 0.010); but no significant difference between before
flucloxacillin treatment and after flucloxacillin treatment
(paired t test: p = 0.179, Wilcoxon: p = 0.262).
Discussion
In this retrospective, single-center study, we showed that treat-
ment with flucloxacillin was associated with a median de-
crease by 37.5% of tacrolimus trough levels. Moreover, the
mean tacrolimus blood trough levels corrected for the dose
before and during flucloxacillin treatment were statistically
significantly different, as well as the mean tacrolimus blood
trough levels corrected for the dose during and after
flucloxacillin treatment. These changes in trough levels can
be of great importance in the clinical management of trans-
plant patients, as unintentional and unnoticed low tacrolimus
levels represent a risk for allograft rejection.
Our findings are in line with the findings of the case series
by Gellatly et al. [12], showing a decrease of tacrolimus
trough levels during flucloxacillin treatment in 4 adult heart
transplant patients. The additional value of our study is that we
were able to quantify the change in trough levels by correcting
the tacrolimus blood trough levels for the prescribed dose.
Moreover, our results show that the reported changes are de-
tectable in different types of organ transplants and throughout
different age groups.
Nevertheless, the study from Muilwijk et al. reported differ-
ent results, stating that flucloxacillin did not decrease tacrolimus
Table 2 Measured outcomes for
comparing tacrolimus trough








Mean blood trough level/dose, μg/L/mg (± SD) 2.3 (± 1.6)*
n = 10
1.3 (± 1.0) 1.9 (± 1.3)





1.3 (0.3–3.3) 1.5 (0.5–3.8)
Median blood trough level/dose ratios
before/during and after/during flucloxacillin
(min-max)
– 1.6 (0.6–3.1) 1.7 (0.7–3.0)
Median blood trough level/dose ratios
before/during and after/during flucloxacillin,
percentage (IQR)
– − 37.5 (26.4–49.7) + 33.7 (22.5–51.4)
Mean ratio before/during and after/during
flucloxacillin treatment (± SD)
– 1.7 (± 0.7) 1.5 (± 0.7)
*n = 11 unless otherwise specified. The mean/median blood trough levels/dose before flucloxacillin treatment
consists of the mean/median of the available tacrolimus trough levels up to 1 year before flucloxacillin treatment,
divided by the dose at time of trough concentration sampling. The mean/median blood trough levels/dose during
flucloxacillin treatment consists of all available tacrolimus trough levels during flucloxacillin treatment starting
from the day after start of flucloxacillin treatment until the last day of flucloxacillin treatment. The mean/median
tacrolimus trough levels/dose after flucloxacillin treatment consists of all the available trough levels divided by
dose starting from 1 day after discontinuation of flucloxacillin up to 1 year after discontinuation of flucloxacillin

















1 Male 26 71 20.5 Lung 9 days
2 Male 39 84 25.9 Liver 14 days





4 Male 38 75 22.4 Lung 5 years,
3 months,
2 days
5 Male 38 93 29.5 Lung 7 years,
6 months,
25 days
6 Male 6 21 15.5 Liver 4 days
7 Male 4 17 14.9 Liver 2 years,
9 months,
26 days
8 Male 72 78 25.5 Kidney 1 day
9 Female 64 49 19.6 Lung 10 years,
4 months,
10 days
10 Female 48 60 23.7 Liver 111 days
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trough levels [10]. However, it has to be kept in mind that the
study from Muilwijk et al. focused on investigating the drug-
drug interaction between flucloxacillin and voriconazole, which
is a CYP3A4 inhibitor. This might mitigate the potential
CYP3A4-inducing effect of flucloxacillin. No details on tacro-
limus doses and trough levels were provided [10]. Moreover,
the potential effect of flucloxacillin on tacrolimus might have
been overlooked in their study since, in general, frequent dose
adjustments occur on the base of frequent trough level control.
This problem can be overcome by correcting the trough levels
for the dose, as done in our study.
The induction of CYP3A4 has been described for several
drugs, including flucloxacillin [8]. It is important to note that
the maximal effect of CYP3A4 induction is achieved over a
period of 10–14 days [20]. After discontinuation of a
CYP3A4 inducer, the time needed to restore the basal level
of metabolism is usually 10–14 days [20]. This delay is also
reported in a case where levels of quinidine decreased during
flucloxacillin therapy and increased again after discontinuing
flucloxacillin [9]. In our retrospective study, a similar delay
was seen. Moreover, the magnitude of the effect was compa-
rable with the effect observed in a report on cyclosporin A
levels after treatment with flucloxacillin, where the mean cy-
closporin A levels fell by 55% within 3 days in seven adult
kidney transplant patients [11]. In addition, similar decrease in
both tacrolimus and everolimus trough levels has been report-
ed during rifampicin therapy [21–23].
A possible mechanism behind the drug-drug interaction
between flucloxacillin and tacrolimus might be that
flucloxacillin activates the nuclear hormone Pregnane X
Receptor (PXR), which induces the expression of both
CYP3A4 and P-gp [8, 11, 20]. This hypothesis is supported
by a recent study in human hepatocytes where flucloxacillin
and dicloxacillin induced CYP3A4 enzymes through the same
PXR mechanism [24]. It is hypothesized that induction of
CYP3A4 does not always have the same effect on drug me-
tabolism as induction of P-gp [25]. This is shown in a study
where CYP3A4, but not P-gp, restricted oral bioavailability of
everolimus in mice despite everolimus being a substrate for P-
gp [4, 26]. However, a study investigating the role of the
potent CYP3A4- and P-gp inducer rifampicin showed similar
effects on both CYP3A4 and P-gp and drugs metabolized by
either P-gp, CYP3A4, or both P-gp and CYP3A4 [23]. Since
PXR induces both CYP3A4 and P-gp, it is unknown if the
decrease in tacrolimus (and probably everolimus) trough
levels observed in this study is a result of either CYP3A4
induction, P-gp induction, or a combination of both [4, 26,
27]. In addition, there may also be other explanations for the
observed lower trough levels of tacrolimus. Unknown factors
such as P-gp pharmacogenetics might be of influence. In our
study, all patients except for one showed the same pattern of
tacrolimus decrease during flucloxacillin therapy. Only pa-
tient 8 showed an increase in mean tacrolimus blood trough
levels corrected for the dose during and after flucloxacillin
treatment. The EHR of patient 8 mentioned, during
flucloxacillin treatment, alternating episodes of obstipation
and laxative-induced diarrhea, which might have played a
role. Although it is known that diarrhea can lead to increased
tacrolimus exposure, it is unknown if laxative-induced diar-
rhea can cause this same phenomenon [28]. Therefore, we
chose not to exclude this patient from our analysis.
However, if this patient were to be excluded, the effect of
Fig. 1 Changes in tacrolimus blood trough levels corrected for the dose.
The blood trough level/dose value before the treatment with flucloxacillin
is set at 100%. Changes in tacrolimus blood trough levels/dose during and
after flucloxacillin treatment are given as a percentage of this value.
Because patient 6 had no data before the flucloxacillin treatment, no
data can be shown
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flucloxacillin would even be greater, with a median decrease
of 40.2% in tacrolimus trough concentration during
flucloxacillin treatment. Further in vivo pharmacokinetic stud-
ies are needed to confirm the hypothesis of a drug-drug inter-
action between flucloxacillin and tacrolimus and assess the
extent of CYP3A4 and/or P-gp induction by flucloxacillin.
We have also considered other possible drug-drug interac-
tions. Among others, we have considered an interaction with
steroid drugs. In our study, nine out of eleven patients used
steroids and some had dose changes during the study period
(data not shown). It has been previously hypothesized that
steroids such as prednisolone can increase the tacrolimus dose
requirement [12]. However, literature considering this effect is
inconsistent and mentions that the interaction might only be
relevant in specific CYP3A5 genotypes [29, 30]. Therefore,
we conclude, in accordance with Gellatly et al., that the po-
tential impact of steroid use is minimal, if at all present [12].
Our retrospective cohort study has several limitations. A first
limitation is the low number of patients included in the study
(n = 11) as this increases the risk of bias. Despite the low number
and diversity of patients in this study with regard to both age and
transplant type, we were nevertheless able to show a relationship
between therapy with flucloxacillin and a decrease in tacrolimus
blood levels. However, a larger study is needed to confirm our
results.
A second limitation is that only retrospective data from the
EHRwere available. Certainly, a prospective pharmacokinetic
cross-over study would offer a more controlled approach for
the assessment of the interaction between flucloxacillin and
tacrolimus. In such a study, the effect of the potential drug-
drug interaction could be measured in healthy volunteers by
comparing tacrolimus area under the curve (AUC) before,
during, and after flucloxacillin treatment.
Another limitation of this study is that we were not able to
gather enough information about the relationship between evero-
limus trough levels and flucloxacillin therapy since only one
patient was treated with flucloxacillin while on everolimus.
Based on the case described in the Introduction section (see
also Online Resource 1, patient 11), and on the fact that everoli-
mus is also metabolized by CYP3A4, a similar effect of
flucloxacillin on everolimus trough levels can be expected. The
effect on everolimus could even be more profound because
everolimus is metabolized primarily by CYP3A4, while tacroli-
mus is metabolized by both CYP3A4 and CYP3A5 [3].
However, this hypothesis can only be confirmed in larger studies.
In conclusion, we reported changes in tacrolimus and
everolimus trough levels during flucloxacillin therapy. Until
our observations are complemented by additional studies on
this subject, we advise physicians and pharmacists to be aware
of a possible drug-drug interaction. Close monitoring of im-
munosuppressant trough levels during flucloxacillin treatment
and up to at least 2 weeks after discontinuation of
flucloxacillin is strongly recommended.
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